Hospital
Hca Health Services of Tennessee, INC.
Hca Health Services of Tennessee, INC. was paid $22.11M by Medicaid between Jan 2018 and Dec 2024, across 61 billing codes. Its largest line is 99283, emergency room visit (moderate) — 48% of everything it billed.
33Billing provider infoHCA HEALTH SERVICES OF TENNESSEE, INC.
HERMITAGE, TN 37076
HERMITAGE, TN 37076
33aNPI1982650024assigned 05/26/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$22.11M
24GClaims291,554
24DCodes billed61
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Tennessee
Rank by total paid#12 of 71
Median peer was paid$6.96M
This provider vs. median3.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 47,495 | $3.35M | |
| 2019 | 49,551 | $3.44M | |
| 2020 | 35,815 | $2.56M | |
| 2021 | 33,307 | $2.77M | |
| 2022 | 38,558 | $3.29M | |
| 2023 | 52,181 | $3.75M | |
| 2024incomplete | 34,647 | $2.95M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 48% | 44,167 | 40,695 | $10.66M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 44% | 39,685 | 34,987 | $9.81M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4.8% | 22,429 | 19,739 | $1.06M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,209 | 1,145 | $181K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,101 | 2,907 | $98K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 3,462 | 3,268 | $64K |
| 80053 | Comprehensive metabolic panel | <1% | 38,353 | 33,539 | $41K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | <1% | 168 | 131 | $31K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,329 | 1,131 | $26K |
| G0378 | Hospital observation service, per hour | <1% | 53 | 39 | $21K |
| G0330 | Facility services for dental rehabilitation procedure(s) performed on a patient who requires monitored anesthesia (e.g., general, intravenous sedation (monitored anesthesia care) and use of an operating room | <1% | 19 | 15 | $17K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,080 | 3,494 | $15K |
49 more codes
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 216 | $14K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 151 | $11K |
| 85027 | <1% | 42,981 | $8K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 123 | $7K |
| G0383 | Level 4 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 29 | $7K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 151 | $6K |
| 84484 | <1% | 3,320 | $5K | |
| 81001 | <1% | 17,143 | $4K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 7,405 | $4K |
| 36415 | Collection of venous blood by venipuncture | <1% | 15,830 | $4K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 160 | $4K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 9,568 | $3K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 371 | $3K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,078 | $1K |
| 83690 | <1% | 5,762 | $1K | |
| 84703 | <1% | 3,183 | $901.74 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,247 | $807.37 |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 16 | $804.31 |
| 71045 | Radiologic examination, chest; single view | <1% | 2,959 | $573.86 |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 13 | $517.72 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 8,328 | $502.33 |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 24 | $369.08 |
| 81025 | <1% | 306 | $100.00 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 369 | $99.99 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,835 | $95.35 |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 336 | $62.14 |
| 87807 | <1% | 125 | $20.17 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,245 | $18.34 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 390 | $3.36 |
| 81003 | <1% | 629 | $2.25 | |
| 87081 | 0% | 803 | $0.00 | |
| 87070 | 0% | 426 | $0.00 | |
| 85730 | 0% | 171 | $0.00 | |
| 83735 | 0% | 310 | $0.00 | |
| 83605 | 0% | 63 | $0.00 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 26 | $0.00 |
| 82077 | 0% | 89 | $0.00 | |
| 87040 | 0% | 76 | $0.00 | |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 18 | $0.00 |
| 74022 | 0% | 14 | $0.00 | |
| 96361 | Intravenous infusion, hydration; each additional hour | 0% | 43 | $0.00 |
| A9270 | Non-covered item or service | 0% | 19 | $0.00 |
| 96376 | 0% | 18 | $0.00 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 0% | 18 | $0.00 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 0% | 12 | $0.00 |
| G1003 | Clinical decision support mechanism medicalis, as defined by the medicare appropriate use criteria program | 0% | 363 | $0.00 |
| 85610 | 0% | 470 | $0.00 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 33 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 234 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCANTRELL, DAVID (CFO)
| Provider | Location | Paid |
|---|---|---|
| Medstop One INC | Cape Girardeau, MO | $729K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.